Grants and Giving
This grant funds educational initiatives to improve clinical decision-making and patient care in transthyretin-mediated amyloidosis (ATTR-CM) by addressing gaps in diagnosis, management, and emerging therapies.
Funder: Alnylam Pharmaceuticals
Due Dates: May 29, 2026
Funding Amounts: Up to $250,000 USD per proposal; multiple awards possible; actual funding may vary from request.
Summary: Supports independent educational initiatives to improve clinical decision-making and patient outcomes in transthyretin-mediated amyloidosis (ATTR-CM).
Key Information: Applications must be submitted via the Alnylam grants portal; only eligible organizations may apply (not individuals or practice groups).
Description
This opportunity supports independent, high-impact educational activities that address gaps in the screening, diagnosis, monitoring, and management of transthyretin-mediated amyloidosis (ATTR-CM). Programs should be designed to enhance real-world clinical decision-making and equip healthcare professionals with actionable knowledge and tools. The focus is on evidence-based, practical education that can be implemented in routine practice, with priority given to proposals addressing disease biology, early diagnosis, treatment decisions, long-term management, multidisciplinary care, and emerging therapies.
